Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses

Hashem H Ghoraba, Amir Akhavanrezayat, Irmak Karaca, Negin Yavari, Sherin Lajevardi, Jaclyn Hwang, Jonathan Regenold, Wataru Matsumiya, Brandon Pham, Moosa Zaidi, Azadeh Mobasserian, Anthony Toan Dong Chau, Christopher Or, Cigdem Yasar, Kapil Mishra, Diana Do, Quan Dong Nguyen

Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA

Correspondence: Quan Dong Nguyen, Spencer Center for Vision Research, Byers Eye Institute, Stanford University, 2370 Watson Court, Suite 200, Palo Alto, CA, USA, Tel +1 650 725 57245, Fax +1 650 736 8232, Email ndquan@stanford.edu

Abstract: Gene therapy has emerged as a research topic of choice in recent years. The eye in particular is one of few organs of the body for which gene therapy has received Food and Drug Administration approval, and it remains a field of great interest for gene therapy development. However, its associated immune and inflammatory reactions may render the treatment ineffective or harmful, which are of particular concern for the eyes due to their susceptibility to inflammation. The severity of immune and inflammatory reactions depends on the choice of vector and its route of administration. Furthermore, most preclinical and clinical studies have shown that the dose of vectors is correlated with the degree of humoral response and ocular inflammation. The route of administration directly impacts the degree of immune and inflammatory reaction. Subretinal delivery produces a weaker humoral response than the intravitreal route. However, some studies have demonstrated that the subretinal delivery induces a stronger inflammatory reaction. On the other hand, several instances of vision loss due to severe late onset intraocular inflammation were reported in a clinical trial involving intravitreal delivery of viral vectors. When compared with the intravitreal route, suprachoroidal gene delivery has been shown to produce weaker humoral response. However, unlike the subretinal space, the suprachoroidal space is not known to have immune privilege status. Inflammatory reactions following ocular gene therapy are typically mild and most clinical and preclinical studies have shown that they can be controlled with topical, local or systemic steroids. However, severe inflammatory responses may occur and require aggressive management to avoid permanent vision loss. Further investigations are required to elucidate and expand our knowledge of inflammatory reactions, and their optimal management, following ocular gene therapy.

Keywords: ocular gene therapy, gene therapy, viral vectors, ocular inflammation, review

Introduction

Gene therapy has become an emerging treatment modality for both inherited and acquired diseases. Therapeutic genes can be delivered into the nuclei of target cells via viral and non-viral vectors. The viral vector approach utilizes the natural ability of viruses to infect human cell genomes. Viral pathologic genetic sequences are replaced by the desired therapeutic genes, and target cells are then infected with the modified viruses leading to incorporation of the therapeutic material into the nuclei. The non-viral vector approach uses different chemical and physical methods to deliver the therapeutic genetic material.1

While gene therapy is used to treat inherited diseases with loss of function mutations, it can also be used to treat acquired diseases. Target cells are infected with therapeutic genes which encode for specific drugs, so that the infected
cells can produce the desired drugs in vivo. This concept has considerable potential; patients can be treated once, and their tissues are transformed into bio-factories that produce the medications indefinitely.

The eye is considered a good candidate for gene therapy; it is small and compartmentalized, requires relatively small numbers of vectors/gene copies, and has special immune response features that can favor viral-mediated gene therapy. Gene therapy for ocular diseases has already been approved by the United States Food and Drug Administration (FDA) to treat pediatric patients with Leber congenital amaurosis harboring a particular gene deficiency, named RPE65. Multiple promising clinical trials are currently being conducted for many other ocular diseases, described below.

Similar to every novel approach, gene therapy has its own set of challenges. Insertional oncogenesis, an inadvertent activation of oncogenes by insertion of transduced genetic material near proto-oncogenes, is a potential limiting factor. The irreversibility and unpredictable longevity of gene therapy effects highlights the lack of control once the treatment is administered.

Different vector types and subtypes induce variable immune and inflammatory responses. These responses can nullify the effect of gene therapy or prevent repeated therapy in the same patient. In addition, different modes of delivery, whether intravitreal, subretinal or suprachoroidal, induce variable immune and inflammatory reactions. Given the etiological complexity of these responses and their detrimental effect on gene therapy efficacy, many studies have tried to analyze the factors that influence these responses.

Recently available data from clinical trials have shown that ocular gene therapy has been associated with severe ocular inflammation with resultant vision loss. Therefore, in this review, we would like to discuss ocular gene therapy with special focus on the resultant immune and inflammatory reactions in the light of the recent updates.

Different Types of Vectors for Ocular Gene Therapy

Viral vectors that are used for ocular gene therapy include adenovirus (AV), adeno-associated virus (AAV), and lentivirus. Non-viral vectors utilize different chemical and physical methods to deliver naked genetic material into the cells.

Viral Vectors

Adenovirus

Adenovirus is a double-stranded deoxyribonucleic acid (DNA) virus that can efficiently transduce dividing and non-dividing cells. It can induce a high amount of protein production by inserting numerous copies of the same gene into a cell. Adenovirus offers multiple advantages, including broad range of tissue tropism (transduction of both retina and anterior segment), a well-characterized genome, ease of genetic manipulation, capacity of carrying large genes, non-replicative nature in a host, and producibility at a large scale.

Although adenovirus was the first vector to be evaluated in clinical trials, it is not currently used in ocular gene therapy clinical trials except for one trial studying retinoblastoma. Adenovirus has fallen out of favor due to the resulting robust immune response that causes inflammation and elimination of the transduced cells. Severe side effects have been reported using adenovirus, as severe as death of a patient with systemic fever and liver damage in a clinical trial for metabolic disease. Although it does not usually replicate inside hosts, a replication-competent virus can be inadvertently created by combination of adenoviral derived vectors with pre-existing adenoviral genome in the targeted cells, causing active systemic adenoviral infection in the patient.

Adeno-Associated Virus

Adeno-associated virus (AAV) is the most commonly used vector for ocular gene therapy trials. AAV is a small (25 nm), replication defective, single-stranded DNA, non-enveloped virus belonging to the Parvoviridae family. It has been evaluated as a gene therapy vector for metabolic, hematological, ophthalmological, muscular, infectious disorders, and cancers. Currently, 13 different AAV serotypes have been identified in primates. They differ in their capsid components and display variable cellular tropism, transduction efficiency, and immunogenicity.

Bennett et al have reported that AAV2 and AAV8 can infect retinal cells from the vitreous, but it was limited to the inner retina. AAV2 has also been used effectively through a subretinal injection to transduce retinal pigment
epithelium (RPE) in a number of gene therapy trials and animal models.\textsuperscript{3,4} For AAV8, subretinal delivery leads to efficient photoreceptor transduction.\textsuperscript{13,14} AAV2 is commonly used in ocular gene therapy trials and is the vector used in the first FDA-approved ocular gene therapy voretigene neparvovec-rzyl (Luxturna\textsuperscript{®}) for Leber congenital amaurosis.\textsuperscript{4}

AAVs deliver the genetic material as an extragenomic circular episome and do not integrate it into the human genome. This mechanism significantly decreases the risk of insertional oncogenesis. Similar to adenovirus, AAVs can also infect dividing and non-dividing cells.\textsuperscript{15,16} AAVs’ limited capacity to carry large-sized genetic material restricts their use in gene delivery for some diseases that are coded by large genes such as Usher syndrome.\textsuperscript{17}

Unlike adenoviruses, AAVs generate relatively mild innate and adaptive immune responses, which allow for stable long-term transgene expression.\textsuperscript{13,15,18,19} These characteristics make AAV vectors particularly suited for applications in a variety of chronic ocular diseases.

Around 70% of the normal population have preexisting antibodies (Abs) against AAV2. On the other hand, AAV8 was isolated from non-human primates (NHPs). Therefore, there is a lower percentage of humans with Abs against it (around 38%).\textsuperscript{20} The presence of antiviral Abs has been correlated with minimal or absent gene expression following gene therapy.\textsuperscript{21} Thus, the use of AAV8-based vector therapy has the potential to be more effective than AAV2. However, there is still cross-reactivity of anti-AAV Abs against different serotypes.\textsuperscript{21}

AAVs can be rapidly eliminated by the humoral immune response in patients who have previously been exposed to the virus.\textsuperscript{22} The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.\textsuperscript{18}

Lentivirus

Lentivirus is a complex, single-stranded ribonucleic acid (RNA) retrovirus that has been studied as a vector. Similar to the two previous vectors, it possesses the ability to induce a stable transduction in both dividing and non-dividing cells in a broad range of target organs.\textsuperscript{23} Lentiviral vectors are derived from primate lentiviruses human immunodeficiency virus (HIV), equine infectious anemia virus (EIAV) and simian immunodeficiency virus.\textsuperscript{3} Lentiviruses integrate their complementary DNA (reverse-transcribed RNA) into the chromosome of target cells enabling sustained gene expression but, like all integrative systems, can increase the risk of insertional mutagenesis and oncogenesis.\textsuperscript{7,24} They can be manufactured in high numbers and their genome can be deleted to reduce the inflammatory response. They also have high transgene carrying capacity allowing delivery of large-sized therapeutic genes that cannot be packed into AAV vectors. Such viral composition is particularly useful for diseases with large causative genes such as Stargardt disease and Usher syndrome.\textsuperscript{22,25,26}

Lentiviruses are possibly more immunogenic than AAVs.\textsuperscript{27} Binley et al found that 5 out of 6 non-human primates that were injected with EIAV in their subretinal space developed a peripheral perivascular retinal whitening. However, this whitening (which probably represented a form of intraocular inflammation) was transient and resolved with treatment.\textsuperscript{28} In general, multiple studies have shown that lentiviruses are relatively safe and can result in effective and sustained gene transduction for a significant time.\textsuperscript{28–30}

Non-Viral Gene Therapy

Non-viral vectors were developed as an alternative to viral vectors to avoid their associated immune responses. Non-viral vectors are used to transfer large DNA-like plasmids, small DNA (eg, oligodeoxynucleotides), and RNA molecules through different chemical and physical methods.\textsuperscript{31}

Chemical methods include lipid-based delivery systems, polymers, and cell-penetrating peptides. They form nano-complexes with the genetic material that can either penetrate the cell membrane or be endocytosed. These complexes also protect genetic material from premature degradation. Nanoparticles carrying genetic material have been shown to effectively transduce the outer retina if injected subretinally.\textsuperscript{6,32}

Physical methods are more variable and technically utilize different approaches to facilitate the genetic material’s delivery into the cells. Examples are electrical pulses, ultrasound, magnetic fields, gene guns, and lasers. High voltage
short electrical pulses (electrotransfection) are highly efficient in transducing the ciliary body to produce the desired drug autonomously.6,32,33

The main advantages of non-viral methods include the lower risk of immune stimulation and insertional mutagenesis (as most do not integrate with chromosomes), the ability to deliver a large amount of genetic materials, and the ease of production. Short-term expression of the transduced genetic material can be considered as a major disadvantage of this method.6,32

**Applications of Gene Therapy in Different Ocular Diseases**

The eye constitutes an excellent site for gene therapy due to its anatomy, ease of access, immune-privileged state, which limits the immune responses and inflammatory reactions against the delivered genetic product, and tight blood-ocular barriers that limit the systemic exposure of the drug. Its relatively small size also grants a minor volume of drug to have effective results. In addition, the assessment of treatment implications can be performed non-invasively via diagnostic imaging, and the second eye can be used as a control group.34 Several studies are focusing on possible gene therapies for an array of ocular diseases from the cornea to the retina. A summary of completed and/or current ocular gene therapy clinical trials can be found in Table 1.

---

**Table 1: Ocular Gene Therapy Clinical Trials***

<table>
<thead>
<tr>
<th>Ocular Site</th>
<th>Disease</th>
<th>Vector (Serotype)</th>
<th>Drug</th>
<th>Route</th>
<th>Development Status</th>
<th>Clinical Trial Number</th>
<th>Trial Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornea</td>
<td>Herpes simplex keratitis</td>
<td>CRISPR/Cas9 mRNA instantaneous gene editing product</td>
<td>BD111: adults single group dose</td>
<td>Intracorneal injection</td>
<td>Phase I/II</td>
<td>NCT04560790</td>
<td></td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Ocular hypertension and open angle glaucoma</td>
<td>siRNA</td>
<td>SYL040012 (bamosiran)</td>
<td>Topical instillation</td>
<td>Phases I &amp; II</td>
<td>NCT01227291, NCT00990743, NCT01739244, NCT02250612</td>
<td></td>
</tr>
<tr>
<td>Retinal diseases</td>
<td>X-linked retinoschisis</td>
<td>AAV (AAV8) AAV8-scRS /IRBPhRS</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT02317887</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinal diseases</td>
<td>X-linked retinoschisis</td>
<td>AAV (AAV2) rAAV2tYF-CB1RSI</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT02416622</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>AAV (AAV2) AAV2-hCHM</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT02341807</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>AAV (AAV2) AAV2.REP1</td>
<td>Subretinal injection</td>
<td>Phase II</td>
<td>NCT02407678</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>AAV (AAV2) AAV2.REP1</td>
<td>Subretinal injection</td>
<td>Phase III</td>
<td>NCT03496012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>AAV 4D-110</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT04483440</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>AAV (AAV2) rAAV2.REP1</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT01461213</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>AAV (AAV2) rAAV2.REP1</td>
<td>Subretinal injection</td>
<td>Phase II</td>
<td>NCT02671539</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)

https://doi.org/10.2147/OPTH.S364200

DovePress

Clinical Ophthalmology 2022:16

Ghoraba et al

Dove Press

Powered by TCPDF (www.tcpdf.org)
### Table 1 (Continued).

<table>
<thead>
<tr>
<th>Ocular Site</th>
<th>Disease</th>
<th>Vector (Serotype)</th>
<th>Drug</th>
<th>Route</th>
<th>Development Status</th>
<th>Clinical Trial Number</th>
<th>Trial Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2)</td>
<td>rAAV2.REP1</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT02077361</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2)</td>
<td>AAV2-REP1</td>
<td>Subretinal injection</td>
<td>Phase II</td>
<td>NCT03507686</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2)</td>
<td>AAV2-REP1</td>
<td>Subretinal injection</td>
<td>Phase II</td>
<td>NCT02553135</td>
<td></td>
</tr>
<tr>
<td></td>
<td>X-linked RP (RPGR gene)</td>
<td>AAV (AAV2)</td>
<td>rAAV2eYF-GRK1-RhPGGR</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03316560</td>
<td></td>
</tr>
<tr>
<td></td>
<td>X-linked RP (RPGR gene)</td>
<td>AAV (AAV2/5)</td>
<td>AAV2/5-RPGR</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03252847</td>
<td></td>
</tr>
<tr>
<td></td>
<td>X-linked RP (RPGR gene)</td>
<td>AAV</td>
<td>4D-125</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT04517149</td>
<td></td>
</tr>
<tr>
<td></td>
<td>X-linked RP (RPGR gene)</td>
<td>AAV (AAV8)</td>
<td>AAV8-RPGR</td>
<td>Subretinal injection</td>
<td>Phase II/III</td>
<td>NCT03116113</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RP (advanced disease)</td>
<td>Optogenetic approach</td>
<td>RST-001</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT02556736</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RP (PDE6B gene)</td>
<td>AAV (AAV2/5)</td>
<td>AAV2/5-hPDE6B</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03328130</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RP (RLBP1 gene)</td>
<td>AAV (AAV8)</td>
<td>CPK850</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03374657</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RP (MERTK gene)</td>
<td>AAV (AAV2)</td>
<td>rAAV2-VMD2-hMERTK</td>
<td>Subretinal injection</td>
<td>Phase I</td>
<td>NCT01482195</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RP (non-syndromic)</td>
<td>Combination of gene therapy and medical device (optogenetic approach via AAV Vector) (AAV2)</td>
<td>G5030-DP (rAAV2.7m8-CAG-ChrimsonR-tdTomato) and G5030-MD (visual interface stimulating glasses)</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT03326336</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV8)</td>
<td>rAAV1hCNGA3</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT02610582</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2)</td>
<td>rAAV2YF-PR1.7-hCNGB3</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT01482195</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2)</td>
<td>rAAV2YF-PR1.7-hCNGA3 (AGTC-402)</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT02935517</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2/8)</td>
<td>AAV-hCNGA3</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03758404</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAV (AAV2/8)</td>
<td>AAV-CNGB3</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03001310</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Ocular Site</th>
<th>Disease (Serotype)</th>
<th>Vector (Serotype)</th>
<th>Drug</th>
<th>Route</th>
<th>Development Status</th>
<th>Clinical Trial Number</th>
<th>Trial Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achromatopsia</td>
<td>AAV (AAV2/8)</td>
<td>AAV-CNGB3 or AAV-CNGA3</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT03278873</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2/4)</td>
<td>rAAV2/4.hRPE65</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT01496040</td>
<td>RPE65</td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2/5)</td>
<td>AAV RPE65</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT02781480</td>
<td>OPTIRPE65</td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>rAAV2-hRPE65</td>
<td>Subretinal injection</td>
<td>Phase I</td>
<td>NCT00821340</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>rAAV 2/2. hRPE65.hRPE65</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT00643747</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>rAAV2-CB58-hRPE65</td>
<td>Subretinal injection</td>
<td>Phase I</td>
<td>NCT00481546</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>rAAV2-CB-hRPE65</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT00749957</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AA2)</td>
<td>AAV2-hRPE65v2</td>
<td>Subretinal injection</td>
<td>Phase I</td>
<td>NCT00516477</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>AAV2-hRPE65v2 (voretigene neparvovec-rzyl, Luxturna)</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT0120839</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>AAV2-hRPE65v2 (voretigene neparvovec-rzyl, Luxturna)</td>
<td>Subretinal injection</td>
<td>Phase III</td>
<td>NCT00999609</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCA (RPE65 gene)</td>
<td>AAV (AAV2)</td>
<td>AAV2-hRPE65v2 (voretigene neparvovec-rzyl, Luxturna)</td>
<td>Subretinal injection</td>
<td>Phase III</td>
<td>NCT04516369</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARMD (wet type)</td>
<td>Lentiviral vector (EIAV)</td>
<td>RetinoStat (OXB-201)</td>
<td>Subretinal injection</td>
<td>Phase I</td>
<td>NCT01301443</td>
<td>GEM</td>
<td></td>
</tr>
<tr>
<td>ARMD (wet type)</td>
<td>AAV (AAV2)</td>
<td>rAAV2-sFLT01</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT01024998</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARMD (wet type)</td>
<td>AAV (AAV2)</td>
<td>rAAV.sFLT-1</td>
<td>Subretinal injection</td>
<td>Phase I/II</td>
<td>NCT01494805</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARMD (wet type)</td>
<td>AAV (AAV8)</td>
<td>AAV8.anti-VEGFab (RGX-314)</td>
<td>Suprachoroidal injection</td>
<td>Phase I/II</td>
<td>NCT03066258</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARMD (wet type)</td>
<td>AAV (AAV8)</td>
<td>AAV8.anti-VEGFab (RGX-314)</td>
<td>Suprachoroidal injection</td>
<td>Phase II</td>
<td>NCT04514653</td>
<td>AAVIATE</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued).

<table>
<thead>
<tr>
<th>Ocular Site</th>
<th>Disease</th>
<th>Vector (Serotype)</th>
<th>Drug</th>
<th>Route</th>
<th>Development Status</th>
<th>Clinical Trial Number</th>
<th>Trial Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARMD (wet type)</td>
<td>ARMD (wet type)</td>
<td>AAV (AAV2)</td>
<td>AAV.7n8-aflibercept (ADVM-022)</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT03748784</td>
<td>OPTIC</td>
</tr>
<tr>
<td>ARMD (dry type)</td>
<td>ARMD (dry type)</td>
<td>AAV (AAV2)</td>
<td>AAVCAGsCD59 (HMR59)</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT03585556</td>
<td></td>
</tr>
<tr>
<td>ARMD (dry type - geographic atrophy)</td>
<td>ARMD (dry type - geographic atrophy)</td>
<td>AAV (AAV2)</td>
<td>AAVCAGsCD59 (HMR59)</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT03144999</td>
<td></td>
</tr>
<tr>
<td>Diabetic retinopathy (w/o CI-DME)</td>
<td>Diabetic retinopathy (w/o CI-DME)</td>
<td>AAV (AAV8)</td>
<td>AAV.8.anti-VEGFab (RGX-314)</td>
<td>Suprachoroidal injection</td>
<td>Phase II</td>
<td>NCT04567550</td>
<td>ALTITUDE</td>
</tr>
<tr>
<td>Optic nerve diseases</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>scAAV2-P1ND4v2</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT02161380</td>
<td></td>
</tr>
<tr>
<td>LHON</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>rAAV2-ND4</td>
<td>Intravitreal injection</td>
<td>??</td>
<td>NCT03428178</td>
<td></td>
</tr>
<tr>
<td>LHON</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>rAAV2-ND4</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT01267422</td>
<td></td>
</tr>
<tr>
<td>LHON</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>rAAV2-ND4</td>
<td>Intravitreal injection</td>
<td>Phase II/III</td>
<td>NCT03153293</td>
<td></td>
</tr>
<tr>
<td>LHON</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>GS010 (rAAV2/2-ND4) Lenadogene Nolparvec</td>
<td>Intravitreal injection</td>
<td>Phase I/II</td>
<td>NCT02064569</td>
<td></td>
</tr>
<tr>
<td>LHON</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>GS010 (rAAV2/2-ND4) Lenadogene Nolparvec</td>
<td>Intravitreal injection</td>
<td>Phase III</td>
<td>NCT02652767</td>
<td>RESCUE</td>
</tr>
<tr>
<td>LHON</td>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>GS010 (rAAV2/2-ND4) Lenadogene Nolparvec</td>
<td>Intravitreal injection</td>
<td>Phase III</td>
<td>NCT02652780</td>
<td>REVERSE</td>
</tr>
</tbody>
</table>

(Continued)
Corneal Diseases
Gene therapy has been studied as a potential treatment option for both inherited and non-inherited corneal diseases. Examples of studied non inherited diseases for gene therapy were Herpes simplex keratitis (HSK), dry eye – Sjogren’s syndrome (SS), corneal graft rejection, and corneal neovascularization.35 Mucopolysaccharidosis (MPS), Meesmann epithelial corneal dystrophy, ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome, aniridia, and Fuchs endothelial corneal dystrophy are among the inherited diseases where corneal gene therapy is applied in several animal studies.35

Glaucoma
As 72% of the cases with primary open-angle glaucoma are hereditary and there is a monogenic inheritance component in juvenile-onset open-angle glaucoma, gene therapy may be beneficial.36 Preclinical and Phase I studies have shown that gene therapy using small interference RNA (siRNA) that suppresses β2-adrenergic-receptor synthesis, via topical drops, might be effective in lowering intraocular pressure (IOP) in glaucoma patients. Phase II studies have also been conducted.37–39

Retinal Disorders
X-Linked Retinoschisis (XLRS)
Because the retina is fragile in patients with X-linked Retinoschisis XLRS, the risk for subsequent retinal detachments increases following gene therapy if performed via the subretinal route. Therefore, the intravitreal route is preferred for the transfer of vectors in this condition.40 There are currently two clinical trials in which the AAV vector expressing RS1 gene is delivered intravitreally to XLRS patients. The preliminary results were reported that the gene product was well tolerated, and ocular adverse events, including dose-related inflammation, resolved using topical and oral corticosteroids.41

Stargardt Disease
Stargardt disease is caused by ABCA4 mutations leading to accumulation of lipofuscin pigment inside the RPE causing degeneration of both RPE and photoreceptor cells.42 A phase I/II clinical trial investigated the utility of EIAV-vector carrying the ABCA4 gene that is delivered through the subretinal route, but it was terminated in 2015.43 Other clinical trials for Stargardt Disease are being planned.

Choroideremia
Choroideremia occurs secondary to a mutation in the CHM gene leading to progressive RPE and photoreceptor cell death.44 There are some challenges for gene therapy in choroideremia, including insufficient resemblance of animal models to functional and morphological manifestations of the disease, and uncertainty of which retinal layer is affected most.45,46 Gene therapy outcomes for choroideremia have been less successful than RPE65-related Leber congenital

<table>
<thead>
<tr>
<th>Ocular Site</th>
<th>Disease</th>
<th>Vector (Serotype)</th>
<th>Drug</th>
<th>Route</th>
<th>Development Status</th>
<th>Clinical Trial Number</th>
<th>Trial Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>LHON</td>
<td>AAV (AAV2)</td>
<td>GS010 (rAAV2/2-ND4) Lenadogene Nolparvovec</td>
<td>Intravitreal injection</td>
<td>Phase III</td>
<td>NCT03293524</td>
<td>REFLECT</td>
<td></td>
</tr>
<tr>
<td>Tumors</td>
<td>Recurrent retinoblastoma</td>
<td>Adenovirus</td>
<td>Oncolytic Adenovirus VCN-01</td>
<td>Intravitreal injection</td>
<td>Phase I</td>
<td>NCT03284268</td>
<td></td>
</tr>
</tbody>
</table>

Note: *Active or completed. Terminated studies were not included. Data from: https://www.clinicaltrials.gov.
Abbreviations: AAV, adeno-associated virus; RP, retinitis pigmentosa; EIAV, equine infectious anemia virus; LCA, Leber congenital amaurosis; ARMD, age-related macular degeneration; CI-DME, central involving diabetic macular edema; LHON, Leber hereditary optic neuropathy.
amaurosis (LCA). There are currently nine clinical trials registered on ClinicalTrials.gov evaluating interventional gene therapies for these patients—all of which use AAV vectors. Only one of them uses the intravitreal route, and the remaining eight deliver the drug subretinally.

Retinitis Pigmentosa and Usher Syndrome

Retinitis Pigmentosa (RP) is a heterogeneous disease, and it occurs in an autosomal recessive (AR) pattern in 50–60% of the cases. The most common genes include RPGR (retinitis pigmentosa GTPase regulator) which accounts for ~70% of X-linked RP; rhodopsin (RHO) which causes ~25% of AD RP, and the Usherin2A (USH2A) gene that is linked to approximately 20% of AR RP. Currently, there are multiple clinical trials assessing different viral and non-viral vectors, through intravitreal and subretinal injections, for different types of RP.

A novel approach, which is described as optogenetic therapy, is also under investigation for retinitis pigmentosa. It is based on delivering genetic information that codes for light sensitive proteins to non-photoreceptor retinal neurons such as ganglion cells, rendering them sensitive to light stimulation and hence, bypassing the photoreceptors. This approach has the potential to improve visual perception in cases of RP and other inherited retinal diseases where the photoreceptors are severely damaged.

Usher syndrome displays AR inheritance with different large-sized causative genes, including MYO7A, USH2A and GPR98. Similar to Stargardt disease, lentiviruses are required to deliver the large-sized genetic material. A single clinical trial was conducted for Usher syndrome with a mutation in MYO7A gene using a lentivirus vector through a subretinal injection, but it was terminated. Recently, a promising phase I/II clinical trial was initiated to evaluate the safety and tolerability of an intravitreal RNA antisense oligonucleotide for Usher syndrome.

Achromatopsia

For achromatopsia, there are six different gene mutations (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6) of which CNGA3 and CNGB3 are the most common. Clinical trials are being conducted targeting these two genes with an AAV vector through subretinal injection.

Leber Congenital Amaurosis

Leber congenital amaurosis (LCA) is an AR disease with mutations in numerous genes. LCA2 occurs specifically due to RPE65 gene mutations, a gene expressed highly in RPE cells. Despite the significant visual impairment in LCA, retinal cells and photoreceptors are relatively spared. Therefore, RPE65-mediated LCA has shown to be a favorable candidate for ocular gene therapy as it requires a certain amount of viable cells to be effective. The FDA approved the first gene therapy for ocular disease following the Phase III clinical trial of AAV2-hRPE65v2 (voretigene neparvovec, Luxturna®) that evaluated the efficacy and safety of bilateral sequential subretinal injections to both eyes in patients with LCA.

The trial with voretigene neparvovec involved 29 pediatric patients older than 3 years with LCA and visual acuity of 20/60 or less. Participants were randomized (2:1) to intervention or control groups. The results of this trial have demonstrated that voretigene neparvovec ameliorated functional vision in RPE65-mediated LCA, and there were no treatment-related serious adverse events. Mild ocular inflammation was reported in only two patients (10%) which was resolved. The authors did not provide details regarding how the ocular inflammation was managed.

Age-Related Macular Degeneration (AMD)

Different vector therapy trials are being conducted for both non-neovascular and neovascular AMD. The safety of subretinally delivered lentiviral EIAV vector expressing endostatin and angiostatin for neovascular AMD has been established with well-tolerated doses, no dose-limiting toxicities, and little to no ocular inflammation. Intravitreal injection of AAV carrying aflibercept gene has also shown very promising results in controlling neovascular AMD disease activity. Additional studies are being conducted to confirm the potential role and utility of vector therapy, via various approaches, including subretinal, intravitreal, and suprachoroidal delivery, in the management of AMD.
Diabetic Retinopathy/Diabetic Macular Edema
Suprachoroidal delivery of an AAV vector carrying an anti-vascular endothelial growth factor (anti-VEGF) fab segment is being evaluated for diabetic retinopathy without central involving macular edema in a phase I clinical trial. A clinical trial is also evaluating an intravitreally delivered AAV vector coding for aflibercept for diabetic macular edema.

Optic Nerve Diseases
Leber Hereditary Optic Neuropathy
Leber hereditary optic neuropathy (LHON), an inherited mitochondrial optic neuropathy related to retinal ganglion cell death, is most commonly linked to ND1 (G3460A), ND4 (G11778A), and ND6 (T14484C) gene mutations. As delivering genes into the ganglion cell mitochondria is difficult, “allotopic expression” strategy (mitochondrial gene expression in nucleus) has been developed. Different trials have demonstrated the safety and efficacy of gene therapy using an AAV vector, delivered through an intravitreal route, for LHON.

Modes of Delivery of Vector Therapy and Associated Ocular Inflammation
Gene therapy can be administered into the eye via different ways such as intravitreal, subretinal, and suprachoroidal routes. Each mode of delivery has its own advantages and unique effects on how the immune system reacts to the vector, which in turn affects the phenotype of ocular inflammation. Different types of intraocular gene delivery are illustrated in Figure 1.

Intravitreal Delivery
The intravitreal route is the traditional route used by ophthalmologists to deliver most intraocular medications into the eye, such as anti-vascular endothelial growth factors (anti-VEGFs), antibiotics, and steroids. The intravitreal route is a convenient choice; it can be administered in office settings and requires fewer instruments and equipment than the subretinal route. In addition, it is surgically simpler, less invasive, and generally safe. Also, this method is more logistically plausible due to its relative ease in delivery. Another advantage of intravitreal gene delivery is its theoretic ability to transduce the whole retinal surface, in contrast to the localized transduction induced by subretinal delivery. Such approach may be beneficial in cases where the targeted cells are not limited only to the macula.

There are two main limitations of the intravitreal route: the inability to transduce outer retina layers and possible immune and inflammatory reaction. The outer retina is the main target of gene therapy for most retinal diseases. Most of the retinal genetic diseases are due to defects in the RPE or photoreceptor cells. Vectors delivered via the intravitreal route have limited ability to transduce the outer retina possibly due to the internal limiting membrane (ILM), evidenced by the improvement of outer retinal transduction after removing or degrading the ILM. However, other studies...
showed that some specially engineered vectors, via directed evolution, can transduce the outer retina after being injected intravitreally.\textsuperscript{65,70} If this result can be reproduced, it may revolutionize gene therapy.

Several reports showed that the vitreous cavity may be considered an immune-privileged space.\textsuperscript{21–73} Yet, the intravitreal vector approach has still shown a different and distinct immune response from subretinal vector delivery.\textsuperscript{74} Studies on humans and NHPs have demonstrated consistently that intravitreal delivery of vectors induces a significant humoral immune response.\textsuperscript{13,21,75,76} The response is marked by the production of Abs, which may not lead to inflammation, but can significantly reduce the efficacy of treatment by attacking and eliminating transduced cells through the neutralizing antibodies. Intravitreal injection of one eye has also been shown to block vector expression in the contralateral eye when injected intravitreally with the same vector, due to the production of neutralizing Abs.\textsuperscript{75}

Reicheletal directly compared the degree of inflammation between intravitreal and subretinal gene therapy.\textsuperscript{13} In their study, they found that the subretinal route caused more anterior and posterior segment inflammation than the intravitreal route, although the intravitreal route caused a stronger humoral response. The finding suggests that there might not be a clear association between intraocular inflammation and humoral response,\textsuperscript{77,78} which is further supported by the work of Bouquetetal\textsuperscript{79} who showed that neither baseline Abs nor the degree of immune response, defined by increased Ab titers, correlated with the degree of intraocular inflammation.

However, Cukrasetal showed that antibody titers were correlated with the degree of inflammation.\textsuperscript{41} In this phase I/II clinical trial, patients were divided into low dose, intermediate dose, and high-dose groups. No patient in the low-dose group had a significant increase in their neutralizing Ab titers. Ab titers increased significantly in both intermediate and high-dose groups. In this study, anterior chamber inflammation correlated significantly with higher Ab levels. All patients of the high-dose group had high Abs titers for 18 months. It should be noted that, in this study, inflammation in all cases in this study was controlled by topical and oral steroids.

In the relatively recent INFINITY clinical trial that evaluated intravitreal AAV for diabetic macular edema (DME), late onset severe intraocular inflammation was observed. In this trial, patients were randomized to three groups: high virus dose (N=12), lower virus dose (N=13) and aflibercept (N=9) groups. Three patients in the high-dose group developed late onset significant inflammation including panuveitis, which resulted in hypotony. All three were treated with pars plana vitrectomy (PPV), silicone oil (SO) and Retisert implantation. None of the patients in the low dose or aflibercept groups developed hypotony. Most patients in both virus treatment groups developed some sort of intraocular inflammation that required difluprednate eye drops beyond a prophylactic post injection 10 weeks period. Most of the high-dose group required additional medications including steroids administered through multiple routes including oral, periocular, and intraocular. Two patients in the high-dose groups required mycophenolate therapy to further suppress intraocular inflammation. Around 50% of the low dose group required additional periocular or intravitreal steroid therapy.\textsuperscript{80}

Interestingly, the same viral concentrations were administered in the Optic trial for AMD, but no hypotony developed and the reported intraocular inflammation was less frequent and less severe, and all incidences were successfully treated with topical steroids only.\textsuperscript{81} This clearly suggests a role of the underlying disease in the development of inflammation in addition to the route and dose. Inflammatory processes are known to be integral in the pathogenesis of diabetic retinopathy,\textsuperscript{82} and this might explain the difference in rates of intraocular inflammation between eyes with diabetic retinopathy and those with AMD, despite being treated with the same vector and concentration.

Subretinal Delivery

Subretinal vector delivery requires pars plana vitrectomy. After completion of the vitrectomy, a macular retinotomy is done via a small gauge cannula. Detachment of the macula is achieved by injecting balanced saline solution followed by vector injection in the preformed bleb.\textsuperscript{14,83}

Using the subretinal approach to deliver vector therapy is well established as it has many advantages. It ensures transduction of outer retinal layers through direct vector delivery. The efficacy of transducing the outer retina by injecting vectors through this route has been reported extensively and consistently.\textsuperscript{4,14,29,84–86} The subretinal space itself has
a special immunological response, which will be discussed below. As mentioned previously, voretigene neparvovec, the only FDA approved ocular gene therapy, is delivered through this approach.

The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole. The technique itself requires significant surgical experience. Ochacovski et al have shown that subretinal injection, in NHPs, can cause mild thinning of the outer layers of the fovea in comparison with an intravitreal injection of the same vector. However, the difference was not clinically significant. Photoreceptor damage was also reported in the phase I trial for the same gene therapy.

The subretinal space is immune privileged and has a deviant immune response. Immune responses to antigens in this space can be similar to anterior chamber associated immune deviation (ACAID); immune responses are suppressed by activating T helper 2 cells. Many studies have shown minimal to absent humoral response to antigens delivered to this space. Furthermore, Anand et al reported suppression of pre-existing cellular immune response to certain antigens after injecting them into the subretinal space. Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies. This beneficial immune response has raised the question of whether it is better not to use steroids with a subretinal injection, as this would theoretically negate the “good” suppressive nature of that deviant immune response.

As mentioned above, few studies found that subretinal route can induce more inflammation compared to the intravitreal route. One may consider this secondary to the surgical technique itself rather than the immune response to the vector; however, Reichel et al showed that subretinal delivery of a vector caused more inflammation than just performing the same surgical procedure without injecting a vector. Nevertheless, to our knowledge, none of the studies that evaluated the subretinal gene delivery have reported devastating panuveitis with loss of vision similar to the above mentioned case that was associated with intravitreal delivery.

Another infrequent but potentially severe immune/inflammatory response to subretinal injection is the poorly understood phenomenon of intraretinal hyperreflective foci, found on optical coherence tomography, following subretinal injection which has been reported in several studies. It was reported at least in two human subjects in two different studies: one study had a subject who suffered from irreversible photoreceptor and vision loss despite steroid use, and another study demonstrated the adverse event in one subject but fortunately resolved following oral steroid treatment. It was also reported in NHPs, but resolved and the retina returned to baseline. To our knowledge, it has not been reported with voretigene neparvovec. It is possible that this reaction represents a unique side effect of a special type of vector, but it was reported with the use of both AAV2 and AAV8 subtypes, suggesting it may not be vector specific.

**Suprachoroidal Delivery**

With both intravitreal and subretinal routes having their disadvantages, suprachoroidal route was studied to overcome these challenges. The suprachoroidal route is less invasive than the subretinal route. It also has the potential of a weaker immune response than the intravitreal route, leading to lower levels of produced antibodies. It can also deliver the vectors to the outer retina, which is a main limitation of the intravitreal route. This route is also being investigated for delivering non-viral vectors with promising results in animals.

Different techniques are being used for suprachoroidal drug delivery. It can be done via a microcatheter, hypodermic needle, or microneedles. Microcatheters require a sclerotomy that requires visualization with a surgical microscope. Cautious dissection of the sclera is done until the scleral-choroidal junction has been reached. The blunt-tipped catheter is then inserted and directed toward the posterior pole, using a light pulp at the tip of the catheter to aid in visualizing its position. The hypodermic needle technique requires merely inserting the needle at an oblique angle through the sclera until a release sensation is just felt. Because it is a somewhat “blind” procedure, it may lead to choroidal or retinal penetration. Another technique utilizes the microneedle which is a very short needle that is applied perpendicularly into the sclera. A large clinical trial employed this method with no serious side effects.

Yiu et al have shown that humoral response to suprachoroidal gene therapy was weaker than the response to the intravitreal route, with levels of neutralizing Abs being significantly lower. To our knowledge, this is the only published study that compared antibody production between the two routes. Although the sample size was small, and the study was
on NHPs, it is very encouraging. This study has also shown that suprachoroidal delivery was associated with widespread transduction of RPE cells, in contrast to the subretinal delivery in which the transduction is localized to the macular bleb.

However, there are issues with the suprachoroidal route as well. There are inconsistent reports about its efficacy in infecting photoreceptors. Two studies involving NHPs showed conflicting results in the efficacy of photoreceptor cell uptake.\textsuperscript{78,101} This may be due to the difference in AAVs capsid or promoter sequence, but further studies are needed. Studies on animals other than NHPs showed that the suprachoroidal route can be used effectively to infect photoreceptors.\textsuperscript{95,101} Another issue is the non-sustainability of gene expression via this route, which can be gradually diminished over 3 months.\textsuperscript{78} Such non-sustainability may be due to the high flow of the choroidal circulation, with a stronger immune response.

Safety of the suprachoroidal route is also an issue. Yiu et al had inadvertent subretinal injection twice by a microneedle when they changed the site of injection from 4 to 10 mm posterior to the limbus.\textsuperscript{78} Other human clinical trials did not report this adverse event.\textsuperscript{99,100}

Inflammation can also occur secondary to the suprachoroidal route. Different degrees of posterior segment inflammation following delivery of the same antigen via intravitreal, subretinal, and suprachoroidal routes have been reported. While the intravitreal route did not cause significant posterior segment inflammation in the form of chorioretinitis, both suprachoroidal and subretinal routes elicited it.\textsuperscript{78} There has been no evidence of a deviant immune response in the suprachoroidal space.

The key differences between intravitreal, subretinal and suprachoroidal modes of delivery are listed in Table 2.

**Electrotransfection**

Electrotransfection is a non-viral gene therapy modality that uses high voltage short electrical pulses that increases cell membrane permeability to naked genetic material. To our knowledge, there are no published data regarding safety of electrotransfection in human eyes. In different studies performed on rabbits and rodents, there were no reported safety issues.\textsuperscript{33,102–104} There were no histological or functional (electroretinogram) toxicities following electrotransfection. Postoperative inflammation could not be accurately assessed as the studies were done on animal models of intraocular inflammation. However, the studies demonstrated that electrotransfection was effective in decreasing ocular inflammation in these models.\textsuperscript{33,102–104}

**Effect of Vector Dose and Constituents on the Type of Ocular Inflammation**

**Viral Capsid and Genome**

Timmers et al have shown that the site of ocular inflammation following intravitreal injection varies according to the presence of the viral genome and/or capsid.\textsuperscript{16} They demonstrated that inflammation in the anterior segment is dependent on the presence of the genome while viral particles with no genome (empty capsids) did not induce an anterior segment reaction. Contrarily, both full viral particles and empty capsids induced vitreal inflammation. Empty capsids induced vitreal inflammation at a lower level than the full particles, implying that capsids induced vitreal inflammation only,

---

**Table 2 Key Differences Between Different Types of Modes of Delivery of Gene Therapy**

<table>
<thead>
<tr>
<th></th>
<th>Invasiveness</th>
<th>Sustainable Outer Retinal Transduction</th>
<th>Immune Privilege</th>
<th>Humoral Response and Antibody Production</th>
<th>Degree of Inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravitreal</td>
<td>+</td>
<td>-</td>
<td>+/-</td>
<td>+++</td>
<td>++++</td>
</tr>
<tr>
<td>Subretinal</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+*</td>
</tr>
<tr>
<td>Suprachoroidal</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>++</td>
<td>+*</td>
</tr>
</tbody>
</table>

**Notes:** *Usually Controlled with topical and/or systemic steroids. +minimal; ++mild; +++moderate; ++++significant. *Multiple cases of severe late onset panuveitis with hypotony and loss of vision were associated with intravitreal gene therapy and required immunosuppressive therapy.
while the genetic material induced inflammation in both anterior and posterior segments. The investigators also found that Abs were generated regardless of the presence of the genome, meaning that it is mainly generated by the capsid.

**Relationship Between Viral Dose and Ocular Inflammation**

Pre-clinical and clinical studies have indicated that gene therapy with AAV can induce dose-dependent innate and adaptive immune responses. This was true in both subretinal and intravitreal deliveries, although the same viral dose induced lower immune responses when delivered via the subretinal route.\(^\text{91,105–107}\) For example, Cukras et al found a dose-dependent response of ocular inflammation.\(^\text{41}\) They evaluated the safety of AAV8 as the vector for delivery of RS1 gene in patients with XLRS caused by RS1 gene mutations in a phase I/II open-label clinical trial. They administered three increasing doses of $1 \times 10^9$, $1 \times 10^{10}$, and $1 \times 10^{11}$ viral particle/eye of AAV8 to nine patients through intravitreal injections. The authors found that ocular inflammation was dose-dependent, but it resolved with administration of oral and topical corticosteroids. There was also a dose-dependent increase in the serum level of systemic antibodies against AAV8.

Another clinical trial on the safety and efficacy of subretinal AAV2 injection in patients with LCA with RPE65 gene deficiency showed comparable findings. Le Meur et al administered low ($1.22–2 \times 10^{10}$) or high ($3.27–4.8 \times 10^{10}$) viral genomes of AAV2 to nine patients.\(^\text{108}\) Although no clinical abnormality was observed, a mild increase in anterior chamber protein flare was seen, indicating ocular inflammation, in only three patients who received the highest dose. The inflammation was minimal and resolved with no consequences after 14 days with local and systemic steroids. In the aforementioned INFINITY trial, rates and severity of ocular inflammation were higher in the high-dose group. Three patients developed severe hypotony in the high dose ($6 \times 10^{11}$) group while none of the low dose ($2 \times 10^{11}$) group showed such complication. The OPTIC trial, which used the same vector type in neovascular AMD patients, did also show a dose dependent inflammatory response but much less in severity when compared with INFINITY trial, implying that the underlying disease should also be considered a factor when assessing the risk of inflammation.\(^\text{30,81,109}\)

Few studies did not show this association between the inflammatory responses and the viral doses. In an open-label phase I/II randomized clinical trial, Bouquet et al\(^\text{79}\) assessed the link between immune response and intraocular inflammation in 15 patients diagnosed with ND4 LHON undergoing ocular gene therapy with rAAV2 vectors. The authors introduced four increasing doses of $9 \times 10^9$, $3 \times 10^{10}$, $9 \times 10^{10}$, and $1.8 \times 10^{11}$ viral genomes per eye through intravitreal injections. Following the injections, mild inflammatory reactions were noted in nearly all patients, regardless of the administered dose. Intensity of inflammation showed no correlation with dosage, and it was also not associated with baseline immune responses and antibody titers. Similarly, Guy et al evaluated the efficacy of AAV2 at two escalating doses of $5 \times 10^9$ and $2.46 \times 10^{10}$ vector genomes in LHON patients.\(^\text{64}\) Their results indicated that only 14% of the eyes showed ocular inflammation over a one-year follow-up, which was not associated with vector dose. One can explain the absence of the dose dependent ocular inflammation in these studies by the small number of patients, which might not have been enough to detect the relationship.

As mentioned, Timmers et al\(^\text{16}\) found that the relationship between the dose and the inflammation may be dependent on the site of intraocular inflammation.\(^\text{16}\) No or weak correlation was found between the dose and degree of anterior segment inflammation (which was incited by the capsids only), while a strong correlation was noticed with vitreal inflammation (incited by both the genome and capsid).

**Management of Intraocular Inflammation Following Gene Therapy**

Steroid administration through different routes has been shown control ocular inflammation following viral vector delivery in most cases. Many studies reported that the resultant ocular inflammation was mild, transient, and controlled by systemic or even topical steroid therapy.\(^\text{4,13,14,29,41,79,87}\) Such control was reported regardless of vector type/subtype or mode of delivery.

Russel et al used perioperative oral steroids at the dose of 1 mg/kg/day, up to 40 mg/day, as a prophylactic method against postoperative inflammation after subretinal delivery of AAV vector.\(^\text{4}\) In their study, only 10% of the patients developed mild transient inflammation, which resolved in all patients. Bouquet et al have not used perioperative steroids in their trial which involved an intravitreal injection of AAV vector.\(^\text{79}\) Most patients who developed postoperative vitreal inflammation were controlled by topical steroids. Oral steroids were used effectively in 2/11 patients who did not respond to topical therapy.
On the other hand, the results of the INFINITY trial clearly show that ocular inflammation following gene therapy does not always respond well to steroids. As mentioned before, some patients responded poorly to intravitreal steroids and required surgery as well as mycophenolate therapy to ameliorate the inflammation.

In such cases where ocular inflammation is significant and can lead to permanent visual loss, aggressive management with zero-tolerance to inflammation should be a rule of thumb to avoid vision threatening complications. It should be noted that the inflammation can develop lately up to 20 weeks following an initial inflammation-free period. Follow-up should be done with due diligence to avoid such late onset, devastating complication.

Conclusions
Gene therapy can be delivered via viral or non-viral vectors. The mode of delivery of gene therapy as well as the underlying ocular pathology influence the postoperative inflammatory and immune responses. While there is no clear evidence of weaker or less inflammatory reactions of the subretinal route when compared with the intravitreal one, immune responses with antibody formations are clearly stronger in the latter. The dose of delivered viral vectors plays a factor in the development of immune and inflammatory responses, and high dose viral vectors were associated with sight threatening ocular inflammation. In general, although the inflammation associated with gene therapy of all routes of delivery has proven to be usually mild and often controlled with steroid therapy, intravitreal route may be associated with late onset sight threatening inflammation.

Suprachoroidal delivery is a potentially simpler and safer approach to deliver gene therapy, but further studies need to determine how unique it is regarding the immune and inflammatory responses. Non-viral gene therapy is also potentially a safe alternative, but its use for inherited diseases can be limited by the short-term expression of transduced genetic materials.

Abbreviations
AAV, adeno-associated virus; Ab, antibody; ACAID, anterior chamber associated immune deviation; AMD, age-related macular degeneration; Anti-VEGF, anti-vascular endothelial growth factor; AR, autosomal recessive; AV, adenovirus; DME, diabetic macular edema; DNA, double-stranded deoxyribonucleic acid; EEC, ectrodactyly-ectodermal dysplasia-clefting; EIAV, equine infectious anemia virus; FDA, Food and Drug Administration; HIV, human immunodeficiency virus; IOP, intraocular pressure; LCA, Leber congenital amaurosis; LHON, Leber hereditary optic neuropathy; MPS, mucopolysaccharidosis; NHP, non-human primates; PPV, pars plana vitrectomy; RHO, rhodopsin; RNA, ribonucleic acid; RP, retinitis pigmentosa; RPE, retinal pigment epithelium; RPGR, retinitis pigmentosa GTPase regulator; siRNA, small interference RNA; SO, silicone oil; SS, Sjogren’s syndrome; USH2A, Usherin2A; XLRS, X-linked retinoschisis.

Funding
There is no funding to report.

Disclosure
Diana Do reports grants from and consultancy for Regeneron during the conduct of the study and grants from and advisory board for Genentech outside the submitted work. Quan Dong Nguyen reports grants and personal fees from Genentech, Novartis, and Regeneron, and personal fees from Rezolute, outside the submitted work. The authors report no other potential conflicts of interest in relation to this work.

References


10. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? 


1. Ghoraba et al.


